Researchers led by a team from Mass General Brigham and the Ragon Institute have discovered why some people living with HIV who are given a treatment called broadly neutralizing anti-HIV antibodies (bNAbs) can safely stop taking standard, lifelong HIV medications and maintain control of the virus for years, while others given the same treatment do not achieve this remission.